Fig. 1From: Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled studyStandard protocol items: recommendation for interventional trials (SPIRIT) figure: trial visits and assessmentsBack to article page